title: [Coronary heart disease in patients with diabetes mellitus].
abstract: Diabetes mellitus is a well-recognized risk-factor for coronary artery disease. It is known that diabetic patients have a two-to fourfold increased risk of mortality or morbidity for cardiovascular diseases compared with the general population. Further, many diabetic patients with coronary heart disease have severe diseased coronary arteries: multi-vessel disease and/or severe stenosed vessel(s). In Japan, the prevalence of diabetic patients is rapidly increasing in these days. This article will review the evaluation for risk of coronary heart disease by measuring glucose level, the prognosis of diabetic patients, and the prevention of cardiovascular event in the patients with diabetes mellitus.
authors.affiliation: Department of Cardiovascular Medicine, Graduate School of Sciences, Kumamoto University.
authors.forename: Masafumi
authors.initials: M
authors.lastname: Nakayama
authors.forename: Hisao
authors.initials: H
authors.lastname: Ogawa
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D003327:Coronary Disease / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D007564:Japan / Q000453:epidemiology; D015995:Prevalence; D011379:Prognosis; D012307:Risk Factors
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D001786:Blood Glucose; D001241:Aspirin